Survodutide for MASH: What to Know

Survodutide is an investigational dual glucagon/GLP-1 receptor agonist studied for metabolic dysfunction-associated steatohepatitis (MASH). In a 48-week phase 2 trial, up to 62% of participants achieved MASH resolution versus 14% on placebo. It is not FDA-approved and remains in phase 3 trials. This guide covers the evidence, safety, and regulatory status.

Survodutide at a glance

• Class: dual glucagon receptor (GCGR) / GLP-1 receptor (GLP-1R) agonist; a 29-amino-acid acylated peptide
• Developer: Boehringer Ingelheim, in collaboration with Zealand Pharma
• Route and frequency: once-weekly subcutaneous injection
• Doses studied in MASH: 2.4 mg, 4.8 mg, and 6.0 mg weekly (phase 2)
• Best-studied for: MASH with liver fibrosis (F1-F3); obesity; type 2 diabetes
• Phase 2 headline: up to 62% MASH resolution without worsening fibrosis vs 14% placebo at 48 weeks
• FDA status: NOT approved; granted Breakthrough Therapy designation for non-cirrhotic MASH (October 2024); phase 3 (LIVERAGE) ongoing
• Important distinction: survodutide is an investigational pharmaceutical — it is NOT a compounded "research peptide" and is not legally available for purchase

What is survodutide?

Survodutide (development code BI 456906) is an investigational peptide drug being developed by Boehringer Ingelheim under a licensing agreement with Zealand Pharma. Structurally, it is a 29-amino-acid acylated peptide carrying a C18 fatty-acid chain that extends its half-life, allowing once-weekly subcutaneous dosing (le Roux et al., 2024, Lancet Diabetes Endocrinol).

What sets survodutide apart from the most familiar metabolic drugs is that it activates two receptors at once. Semaglutide (Ozempic, Wegovy) targets a single receptor, GLP-1. Tirzepatide (Mounjaro, Zepbound) targets two, GLP-1 and GIP. Survodutide instead pairs GLP-1 receptor activation with glucagon receptor activation — a different second target with direct effects on the liver.

Survodutide is being studied across three connected conditions: type 2 diabetes, obesity, and MASH (formerly called NASH). This article focuses on the MASH program, where survodutide has drawn the most attention. For background on the GLP-1 drug class as a whole, see our GLP-1 peptides explained guide.

How does survodutide work in the liver?

The rationale for dual agonism in liver disease comes down to what each receptor does.

The GLP-1 receptor arm reduces appetite and slows gastric emptying, which lowers food intake and drives weight loss — the same mechanism behind semaglutide and tirzepatide. Because MASH is tightly linked to obesity and insulin resistance, weight loss alone improves the underlying disease.

The glucagon receptor arm is the differentiator. Glucagon receptor activation is thought to increase energy expenditure and, importantly, to directly increase fat oxidation (fat burning) in the liver, which may reduce the lipotoxic fat that drives inflammation and scarring in MASH (Sanyal et al., 2024, NEJM). In preclinical work, survodutide showed potent activity at both receptors, with comparable potency at the glucagon and GLP-1 receptors.

The theory researchers are testing is that hitting the liver from two directions — less fat coming in (via weight loss and reduced intake) and more fat burned off (via glucagon-driven hepatic fat oxidation) — could outperform GLP-1 activation alone for liver-specific outcomes. Whether that theoretical edge translates into superior long-term outcomes is what the ongoing phase 3 program is designed to answer.

What does the phase 2 MASH trial show?

The pivotal evidence comes from a phase 2 randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine (Sanyal et al., 2024, NEJM; PMID 38847460).

The trial enrolled 293 adults with biopsy-confirmed MASH and fibrosis stage F1 through F3. Participants were randomly assigned to once-weekly subcutaneous survodutide at 2.4 mg, 4.8 mg, or 6.0 mg, or to placebo, for 48 weeks (a 24-week dose-escalation phase followed by 24 weeks of maintenance).

MASH resolution without worsening of fibrosis (the primary endpoint) occurred in:

Data from Sanyal et al., 2024, NEJM.

The 4.8 mg dose produced the strongest MASH-resolution signal. Boehringer also reported that within the subgroup with moderate-to-advanced fibrosis (F2-F3), up to 64.5% of survodutide-treated participants achieved fibrosis improvement versus 25.9% with placebo (Boehringer Ingelheim, June 2024) — though, as with any subgroup analysis, that figure carries more uncertainty than the overall result.

A key caveat: this is phase 2 data over 48 weeks. It establishes a strong biological signal but does not establish long-term clinical outcomes (such as preventing cirrhosis, liver failure, or death), which require the larger and longer phase 3 trials now underway. For a comparison drug studied for the same indication, see our tirzepatide for MASH overview.

What dose of survodutide was studied?

In the MASH phase 2 trial, survodutide was given as a once-weekly subcutaneous injection at maintenance doses of 2.4 mg, 4.8 mg, or 6.0 mg, reached through a gradual dose-escalation schedule over the first 24 weeks (Sanyal et al., 2024, NEJM). The phase 3 LIVERAGE program is studying a regimen titrated to a maximum dose of 6 mg weekly (ClinicalTrials.gov, NCT06632444).

Because survodutide is investigational, there is no approved dose, no commercially available product, and no over-the-counter or compounded version that is legal to obtain. The doses above describe how the drug was administered inside controlled clinical trials with medical supervision and gradual titration to manage side effects — they are not a protocol anyone can or should attempt independently.

Consult your healthcare provider before starting any peptide protocol. The only legitimate way to receive survodutide today is by enrolling in a clinical trial.

What are the side effects and safety considerations?

In the phase 2 MASH trial, the most common adverse events were gastrointestinal, and they occurred far more often with survodutide than placebo (Sanyal et al., 2024, NEJM):

• Nausea: 66% (survodutide, combined) vs 23% (placebo)
• Diarrhea: 49% vs 23%
• Vomiting: 41% vs 4%

Most GI effects clustered during the rapid dose-escalation phase, which is why slow titration matters. Adverse events leading to discontinuation occurred in 20% of survodutide-treated participants (16% from GI effects) versus 3% on placebo. Serious adverse events were similar between groups — 8% with survodutide and 7% with placebo (Sanyal et al., 2024, NEJM).

These tolerability concerns mirror the broader incretin drug class: GI side effects are the dominant issue, generally manageable with slow titration, but a meaningful minority of people cannot tolerate the higher doses. Because the glucagon arm raises additional questions around heart rate, blood pressure, and glucose handling, long-term safety is one of the main things the phase 3 program is designed to characterize. A related obesity sub-study reported that survodutide was associated with blood-pressure reductions (le Roux et al., 2025, Diabetes Obes Metab).

This is investigational, not a settled safety profile. Consult your healthcare provider before starting any peptide protocol, and never combine GLP-1 class drugs without medical oversight.

Is survodutide FDA-approved or legal to buy?

No. As of June 2026, survodutide is not approved by the FDA for any indication and is not commercially available.

In October 2024, the FDA granted survodutide Breakthrough Therapy designation for the treatment of adults with non-cirrhotic MASH and moderate-to-advanced fibrosis — a status that can speed development and review but is not an approval (Boehringer Ingelheim, October 2024). On the strength of the phase 2 data, Boehringer launched two phase 3 trials: LIVERAGE, in non-cirrhotic MASH with F2-F3 fibrosis, enrolling roughly 1,800 adults (ClinicalTrials.gov, NCT06632444), and LIVERAGE-Cirrhosis, in compensated cirrhosis.

A critical distinction for readers: survodutide is an investigational pharmaceutical, not a "research peptide." It is fundamentally different from compounded peptides such as BPC-157 or TB-500. Survodutide is not sold by online peptide vendors, is not on the FDA's 503A or 503B compounding bulk-substance lists, and is not among the peptides under review at the FDA's Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026 (FDA, 2026). Any product marketed online as "survodutide" outside a clinical trial should be treated as unverified and potentially unsafe.

For now, the only legal route to survodutide is clinical-trial enrollment. The first FDA-approved drug specifically for MASH is resmetirom (Rezdiffra), an oral thyroid hormone receptor-β agonist approved in March 2024 — a separate medication from survodutide (Keam, 2024, Drugs). Legal status varies by jurisdiction; consult a lawyer for binding advice, and your healthcare provider for medical decisions.

How does survodutide compare to other MASH and obesity drugs?

Survodutide sits among several incretin-based and liver-targeted agents being developed for metabolic liver disease:

• Resmetirom (Rezdiffra): the only FDA-approved MASH drug; oral; works through thyroid hormone receptor-β, a completely different mechanism (Keam, 2024, Drugs).
• Semaglutide: GLP-1 single agonist; extensively studied for obesity and diabetes and investigated for MASH.
• Tirzepatide: GLP-1/GIP dual agonist; also studied in MASH.
• Survodutide: GLP-1/glucagon dual agonist; the glucagon arm is its distinguishing liver-directed feature.

Beyond the liver, survodutide has shown substantial weight loss. In its phase 2 obesity trial, survodutide produced dose-dependent body-weight reductions, with the highest doses driving weight loss well into the mid-teens by percentage over 46 weeks (le Roux et al., 2024, Lancet Diabetes Endocrinol). In type 2 diabetes, survodutide lowered HbA1c and body weight in a dose-ranging trial that included an open-label semaglutide comparator (Blüher et al., 2023, Diabetologia).

No head-to-head MASH outcome trial has yet established whether survodutide's dual mechanism beats GLP-1-only or GLP-1/GIP approaches on hard liver endpoints. That is the open question.

Frequently asked questions

Q: What is survodutide used for? A: Survodutide is an investigational drug being studied for three related conditions: metabolic dysfunction-associated steatohepatitis (MASH), obesity, and type 2 diabetes. It is not approved for any of these uses yet. The most advanced and closely watched program is in MASH, where it received FDA Breakthrough Therapy designation in October 2024 and is now in phase 3 trials. Discuss any metabolic or liver condition with a healthcare provider.

Q: Is survodutide FDA-approved? A: No. As of June 2026, survodutide is not approved by the FDA for any condition. It holds Breakthrough Therapy designation for non-cirrhotic MASH — a development status, not an approval — and is being evaluated in phase 3 LIVERAGE trials. The only FDA-approved drug specifically for MASH is resmetirom (Rezdiffra), which is a different medication.

Q: How is survodutide different from semaglutide or tirzepatide? A: All three are once-weekly injectable peptides, but they hit different receptors. Semaglutide activates GLP-1 only. Tirzepatide activates GLP-1 and GIP. Survodutide activates GLP-1 and the glucagon receptor. The glucagon component is thought to increase energy expenditure and liver fat oxidation, which is the rationale for testing it specifically in liver disease. Whether this translates to better outcomes is still under study.

Q: How effective was survodutide for MASH in trials? A: In a 48-week phase 2 trial of 293 adults, up to 62% of those on the 4.8 mg dose achieved MASH resolution without worsening fibrosis, versus 14% on placebo (Sanyal et al., 2024, NEJM). Up to 67% achieved at least a 30% reduction in liver fat. These are encouraging phase 2 results, but long-term outcomes are still being studied in phase 3.

Q: What are the side effects of survodutide? A: In trials, the most common side effects were gastrointestinal — nausea (66%), diarrhea (49%), and vomiting (41%) in survodutide-treated participants, mostly during dose escalation. About 20% of participants discontinued due to adverse events. This profile is consistent with other incretin-based drugs. Long-term safety is still being characterized. Consult your healthcare provider before considering any such medication.

Q: Can I buy survodutide? A: No. Survodutide is investigational and not commercially available. It is not sold by peptide vendors, is not a compounded "research peptide," and is not on the FDA's 503A/503B compounding lists. The only legitimate way to receive it is by enrolling in a clinical trial. Any product sold online as "survodutide" should be treated as unverified and potentially unsafe.

Q: When might survodutide be approved? A: There is no confirmed approval date. Survodutide entered phase 3 trials (LIVERAGE and LIVERAGE-Cirrhosis) in late 2024, with the cirrhosis outcomes trial designed to run roughly 4.5 years. Approval, if it comes, depends on those results and FDA review. [VERIFY: any specific projected approval year] — treat any specific approval timeline you see elsewhere with caution.

References

1. Sanyal AJ, Bedossa P, Fraessdorf M, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024;391(4):311-319. PMID: 38847460. https://pubmed.ncbi.nlm.nih.gov/38847460/ · DOI: 10.1056/NEJMoa2401755
2. le Roux CW, Steen O, Lucas KJ, et al. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162-173. PMID: 38330987. https://pubmed.ncbi.nlm.nih.gov/38330987/ · DOI: 10.1016/S2213-8587(23)00356-X
3. Blüher M, Rosenstock J, Hoefler J, et al. Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia. 2024;67(3):470-482. PMID: 38095657. https://pubmed.ncbi.nlm.nih.gov/38095657/ · DOI: 10.1007/s00125-023-06053-9
4. le Roux CW, Jastreboff AM, Fitch A, et al. Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity. Diabetes Obes Metab. 2025;27(2):993-996. PMID: 39582349. https://pubmed.ncbi.nlm.nih.gov/39582349/ · DOI: 10.1111/dom.16052
5. Keam SJ. Resmetirom: First Approval. Drugs. 2024;84(6):729-735. PMID: 38771485. https://pubmed.ncbi.nlm.nih.gov/38771485/ · DOI: 10.1007/s40265-024-02045-0
6. ClinicalTrials.gov. LIVERAGE: A Study to Test Whether Survodutide Helps People With NASH/MASH Who Have Moderate or Advanced Liver Fibrosis. NCT06632444. https://clinicaltrials.gov/study/NCT06632444
7. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026